Lionel Pochet is a Professor at the University of Namur, active in drug design, thrombosis research, and analytical chemistry. His work focuses on coagulation cascade inhibitors and fragment-based drug discovery. Namur Medicine & Drug Innovation Center Namur Thrombosis and Hemostasis Center Namur Research Institute for Life Sciences His research spans coumarin derivatives , FXIIa inhibition , and covalent probes for protein interactions. Recent projects include targeted covalent inhibitors for Mycobacterium tuberculosis and lactate dehydrogenase. Key publications highlight pharmacological evaluation , mass spectrometry , and structural chemistry applications in drug discovery. Awards and grants are not explicitly mentioned in the provided text.
Jean-Michel Dogné is a full Professor at the Faculty of Medicine, University of Namur, where he leads research in clinical pharmacology and toxicology. He is affiliated with several key research centers including the Namur Medicine & Drug Innovation Center, the Namur Thrombosis and Hemostasis Center, and the Namur Nanosafety Center. His work is integral to the Namur Research Institute for Life Sciences and he actively contributes to EU-level pharmacovigilance through his role in the EMA's PRAC committee. Education: Doctor of Pharmacy, Université de Liège (2000), Thesis: Drug design and development His research focuses on anticoagulant therapy, thrombosis, drug safety, and personalized medicine , with strong emphasis on clinical applications in cancer and infectious diseases. He has led major projects such as COVILAB (on COVID-19) and studies on BCR-ABL inhibitors in leukemia. His work often involves systematic reviews, meta-analyses, and biomarker discovery, contributing to evidence-based medicine. The 15 most recent publications reflect a sustained focus on thrombosis in oncology, pharmacovigilance, anticoagulants, and pandemic research , with increasing integration of regulatory science and model-informed drug development. His work spans clinical trials, laboratory investigations, crystallography, and public health policy , demonstrating a multidisciplinary approach to pharmaceutical innovation. Scientific Awards: Prix Léo Pharma Cancer & Thrombosis (2017) Jean-Michel Dogné has supervised over 40 students and researchers, contributing significantly to training the next generation of clinical pharmacologists. He has secured numerous national and international grants, particularly in the areas of drug safety and thrombosis. His collaborative network is extensive, involving institutions across Europe and participation in EU-level regulatory bodies. He is a key member of the Clinical Pharmacology Research Group and leads major initiatives such as the MP-EMA project. His team operates within state-of-the-art facilities at the University of Namur, focusing on translational research from bench to bedside.
Jonathan Douxfils is a Professor at the University of Namur, affiliated with the Namur Research Institute for Life Sciences and the Thrombosis and Hemostasis Center. His expertise lies in pharmacology, thrombosis, and anticoagulant therapies. He holds a Pharm.D. and Ph.D. from the University of Namur and a Master of Pharmacy from Université Catholique de Louvain. Key roles include CEO of Qualiblood, Co-Chairman of the International Society on Thrombosis and Hemostasis's SSC Control of Anticoagulation, and Pharmacovigilance Expert at the Federal Agency of Medicines and Health Products. His research focuses on anticoagulant safety, thrombosis risk assessment, and innovative diagnostic tools like the DOAC Dipstick. Notable awards include the Alfers Prize 2022, Eberhard F. Mammen Young Investigator Award 2019, and multiple recognition in hemostasis research. He leads projects such as NucleoGlio (glioblastoma diagnostics) and GT4HEALTH (gene therapy research). He has supervised 19 thesis works and contributed to over 436 research outputs. His work aligns with UN SDGs in health and innovation.
Laure Morimont is a Researcher at the Namur Research Institute for Life Sciences, part of the Clinical Pharmacology and Toxicology Research Unit. Her research focuses on thrombosis, coagulation disorders, and the effects of hormonal therapies and contraceptives on blood clotting. She contributes to projects like the COVILAB initiative on SARS-CoV-2 and the HIC Project evaluating hormone-induced coagulopathy. Morimont has received awards including the 2021 Best Oral Presentation and the 2020 Belgian MedTech Program recognition. Her work spans clinical pharmacology, venous thromboembolism risk assessment, and coagulation testing innovations. Key Projects: Clinical Pharmacology Research Group (2022–present) COVILAB: SARS-CoV-2 investigations (2020–present) HIC Project: Hormone-induced coagulopathy evaluation (2019–2023) Research Interests: Thrombin generation and anticoagulant efficacy Risk assessment of hormonal therapies Coagulopathy in pregnancy and cancer patients Her articles emphasize anticoagulant pharmacodynamics, contraceptive safety, and clinical diagnostic tools like the DOAC Dipstick. Morimont actively collaborates internationally and presents at conferences such as the ISTH Congress. She also leads studies on thrombosis prediction models and coagulation assay standardization.
Kathleen Freson is a Professor at the Faculty of Medicine , KU Leuven. She serves as Director of the Biomedical Sciences Doctoral School and Head of the Center for Molecular and Vascular Biology . Her research focuses on genetic hemostasis disorders , thrombophilia , and inherited platelet defects , with emphasis on genotype-phenotype correlations and omics-based disease modeling . Key projects: Multigene panels for thrombophilia, whole-genome sequencing for platelet disorders, functional assessment of anticoagulant variants Her recent publications address venous thromboembolism epidemiology , neurodevelopmental disorders linked to snRNA mutations , and clinical applications of genetic sequencing in bleeding diseases . She collaborates with institutions like the KU Leuven Institute for Rare Diseases and contributes to ISTH nomenclature guidelines .
Marie Didembourg is a researcher at the University of Namur, affiliated with the Department of Clinical Pharmacology and Toxicology and the Namur Thrombosis and Hemostasis Center (NTHC). Her work contributes to the UN Sustainable Development Goals, particularly in the area of Good Health and Well-being. She focuses on the interplay between hormonal therapies and coagulation disorders, with a strong emphasis on thrombin, estrogens, and anticoagulant pharmacodynamics. Research Interests: Hormone-induced coagulopathy, thrombin interactions, venous thromboembolism, neutralizing antibodies in pregnancy, and comparative evaluation of hormonal therapies. Recent Activities: Presented at the 31st BTSH, ISTH 2024, and the 21st World Congress of the International Society of Gynecological Endocrinology. Media Contributions: Co-authored press releases on natural estrogen-based contraceptives and SARS-CoV-2 antibody responses during pregnancy.
Bernard Chatelain is a prominent researcher affiliated with the Namur Thrombosis and Hemostasis Center and the Catholic University of Louvain (UCLouvain), specializing in thrombosis, hemostasis, and anticoagulant therapies. His work bridges clinical laboratory practices with research on fibrinolytic systems, microparticles in thrombotic diseases, and thrombotic risk management during pandemics like COVID-19. Recent Research Focus: Development of integrative assays for fibrinolytic system phenotyping, optimization of coagulation testing protocols, and analysis of anticoagulant impacts on platelet function. Collaborations: Active partnerships with institutions like UCLouvain, Université de Namur, and international hemostasis laboratories. His scientific contributions include over 146 research outputs, with recent publications addressing: Standardization of prothrombin time measurements using novel thromboplastin reagents. Time-sensitive variables in platelet testing accuracy. Thrombotic risk mitigation frameworks during global health crises. Chatelain’s work has informed clinical guidelines and been referenced in policy documents, highlighting its translational significance.
Lorian RONVAUX is a Researcher in the Clinical Pharmacology Research Group , focusing on biomarker development for complex diseases. Their work spans glioblastoma , thrombosis , and sCOVID-19-related critical care . Research Areas : Liquid biopsy, NETosis, nucleosome biomarkers, glioblastoma diagnostics, thrombin activity, kinase/PARP inhibitor interactions. Recent Projects include: Development of glioblastoma diagnostic/prognostic biomarkers (GLIOMARKERS) Drug-induced thrombosis in cancer therapies (DIT project) Mechanistic studies of NETosis in septic shock and severe COVID-19 Collaborations involve supervisors like Prof. Jean-Michel Dogné and Prof. François Mullier, with multidisciplinary teams across clinical and translational research.
Hugues Jacqmin holds a Doctorate in Biomedical and Pharmaceutical Sciences from the Faculty of Medicine at the University of Namur, Belgium. His research focuses on hematology and thrombosis, particularly in anticoagulant therapy, platelet function analysis, and blood coagulation disorders. Research interests include: Standardization of hemostasis testing Impact of anticoagulation on diagnostic accuracy Thrombotic risks in severe diseases like COVID-19 Platelet testing methodologies Recent work involves evaluating thromboplastin reagents, analyzing plasma variability in lupus anticoagulant testing, and studying prothrombotic states in critical care patients. Collaborations span clinical and biomedical fields, with co-authors from hematology, pharmacy, and critical care disciplines.
Dr. Adeline WANNEZ is a researcher at the Faculty of Medicine, University of Namur, specializing in thrombosis mechanisms and extracellular vesicle biology. Her work bridges biomedical science with clinical hematology. Doctorate in Biomedical and Pharmaceutical Sciences (2018) Master in Biomedicine (2014) Research Interests: Focuses on blood coagulation risks , extracellular vesicle dynamics , and hematological malignancies . Key methodologies include flow cytometry and clot-based assays . Her publications (2016-2020) cover thrombosis in leukemia patients microRNA biomarkers in lymphoma procoagulant activity of blood products flow cytometry protocols for vesicle analysis
Emilie Catry is a researcher at Catholic University of Louvain (UCLouvain) , contributing to clinical laboratory medicine and healthcare sustainability. She is actively involved in multidisciplinary studies on diagnostic testing, with a focus on Improving appropriateness of laboratory tests in intensive care units Environmental and economic impacts of clinical testing Coagulation disorder diagnostics Vaccine-induced immunity to SARS-CoV-2 variants Recent trends in her publications highlight intersections of clinical pathology , sustainable healthcare , and immunodiagnostics , appearing in journals like The Journal of Applied Laboratory Medicine and Clinical Chemistry and Laboratory Medicine . Collaborations with experts like François Mullier and Laure Devis underscore her network in laboratory medicine research. Press coverage by UCLouvain in 2024 highlighted her team's findings on sustainability in clinical testing. No formal student advisories, scientific awards, or lab affiliations are explicitly mentioned in the provided data.
Jonathan Evrard is a researcher affiliated with the University of Namur , specializing in Clinical Pharmacology . His work primarily focuses on anticoagulant therapy, thrombosis, and hemostasis, with a strong emphasis on developing and evaluating analytical tools like FibWave for coagulation assessment. Key projects : CAF (clot formation assessment), BIOCOAG (biological anticoagulation control), POC-FibWave (fibrin clot automation), HIC (hormone-induced coagulopathy). Research interests : Anticoagulant pharmacology, clot waveform analysis, thrombin generation, fibrinolysis, and hormonal impacts on coagulation. Collaborations : Works closely with Prof. Jean-Michel Dogné, Prof. Jonathan Douxfils, and the Namur Thrombosis & Hemostasis Center (NTHC).
Celine Bouvy is an active Researcher at the University of Namur, specializing in hematology and clinical pharmacology. She contributes significantly to the Clinical Pharmacology Research Group and the COVILAB project (focused on COVID-19 laboratory investigations), working alongside supervisors including Jean-Michel Dogné and Jonathan Douxfils. Her doctoral research culminated in a 2017 PhD thesis titled Roles of extracellular vesicles and their microRNA cargo in chemotherapeutic resistance, pro-coagulant phenotype and as potential biomarkers in diffuse large B-cell lymphoma , supervised by Jean-Michel Dogne and Colette Chatelain. Bouvy's research centers on thrombin generation dynamics, coagulation disorders, and women's health. Her work examines thrombin activity in postmenopausal women using estetrol, activated protein C resistance diagnostics, and anticoagulant monitoring techniques. She investigates how hormonal therapies impact hemostasis, metabolism, and bone health, with strong implications for cardiovascular risk assessment in aging women. Her publication trends reveal consistent focus on thrombosis diagnostics (75% of research output), anticoagulant monitoring (66% of projects), and women's health applications (36% fingerprint concentration). Recent work emphasizes thrombin generation testing standardization and COVID-19-related coagulopathy investigations. Scientific Recognition: Poster award (2015) for conference presentation Bouvy actively participates in major research consortia including the Clinical Pharmacology Research Group (active since 2022) and COVILAB project (since 2020), contributing to 57 total research outputs including 22 articles, 25 posters, and 9 conference contributions. Her work receives consistent attention with 351 Scopus citations and 10 h-index. She operates within the university's clinical pharmacology infrastructure, collaborating extensively on thrombosis diagnostics and anticoagulant monitoring projects, with particular focus on translating laboratory findings to clinical applications in women's health and pandemic response.
Christelle Orlando serves as an Unpaid guest professor (mapped to Visiting Professor) in the School of Clinical Sciences and Researcher in Clinical Biology at Vrije Universiteit Brussel, with continuous scientific collaboration at Universitair Ziekenhuis Brussel's Hemostasis lab since 2005. She oversees routine and specialized coagulation testing while contributing to translational research through the Translational Oncology Research Center affiliation. Her academic credentials include a Master's degree in Medical Sciences (2005) and PhD in Medical Sciences (2021), both from Vrije Universiteit Brussel, focusing on minimal residual disease detection in pediatric leukemia and novel insights into inherited antithrombin deficiency respectively. Dr. Orlando's research centers on inherited thrombophilia , with specialized expertise in antithrombin deficiency mechanisms and diagnostics. She investigates genotype-phenotype correlations in coagulation disorders, develops laboratory validation protocols, and examines clinical implications of rare mutations like the Budapest 3 variant. Her work bridges molecular pathology with clinical hemostasis practice through rigorous diagnostic assay evaluation. Recent publications demonstrate evolving expertise from case-based mutation analysis toward comprehensive diagnostic methodology. Her 2024-2025 work shows increasing emphasis on analytical validation of hemostasis instruments and standardization of antithrombin testing , reflecting field-wide shifts toward precision diagnostics in thrombophilia. Her contributions have earned significant recognition: Paul Capel Prize (2010 and 2011) Prijs Edmond Secq en André Houssiau 2022 for inherited bleeding disorders research (awarded 2023) Dr. Orlando actively mentors next-generation researchers, supervising Master's theses like Bouteille, S.P.'s 2022 work on protein C deficiency genotype-phenotype correlations. Her professional engagements include conference chairing (Werfen SAC Meeting Benelux 2024), invited lectures on thrombophilia testing standardization, and peer review for Haemophilia journal, demonstrating leadership in hemostasis education and quality assurance. Within UZ Brussel's Hemostasis lab, she leads specialized coagulation testing initiatives while collaborating with the Translational Oncology Research Center on projects intersecting coagulation disorders and cancer-related thrombosis, driving innovation in diagnostic protocols for complex clinical scenarios.
Christel Van Geet is a full professor at the Faculty of Medicine of KU Leuven , affiliated with the Center for Molecular and Vascular Biology and the KU Leuven Cancer Institute . She leads research on genetic mechanisms underlying bleeding disorders, thrombosis, and platelet dysfunction, with a focus on genomic medicine and translational hematology. Blood group O and inhibitor risk in haemophilia A β-globin haplotypes in sickle cell anemia Ribosome dysfunction in thrombocytopenia Clinical implementation of genetic testing Her work spans molecular biology, clinical diagnostics, and global health initiatives in Central Africa. She collaborates extensively in international consortia like PedNet and contributes to advancing gene-based therapies such as emicizumab for hemophilia.
